Sangamo Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and a Favorable Safety Profile

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

BRISBANE, Calif. --(BUSINESS WIRE)--May 3, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in fireside chats at the following investor conferences: BofA Securities 2021 Health Care Conference Date: Thursday, May 13